Aida Pharma Subsidiary Commenced Preclinical Study of Vasostatin-Apo2L, Potential Anti-Cancer Therapy
A subsidiary of China’s Aida Pharmaceuticals, Inc. (OTC: AIDA) - Shanghai Qiaer Biotechnology – has initiated the preclinical research of the company’s potential anti-cancer treatment Vasostatin-Apo2L.
A recombinant fusion protein, Vasostatin-Apo2L is a potential tumor growth inhibitor.
The treatment may integrate the function of an extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth with similar results of Rh-Apo2L, the Company's existing anti-cancer treatment currently in Phase II trials, which induces the apoptosis (cellular death) of cancer cells.
Based in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China, Aida Pharmaceuticals, Inc. is one of mainland China's leading pharmaceutical companies.
Read the full press release.
Comment Preview